Medifast (NYSE:MED - Get Free Report) is anticipated to announce its Q1 2025 earnings results after the market closes on Monday, April 28th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $114.85 million for the quarter. Medifast has set its Q1 2025 guidance at -0.500-0.000 EPS.
Medifast (NYSE:MED - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The specialty retailer reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.16) by $0.26. Medifast had a return on equity of 10.64% and a net margin of 0.35%. The business had revenue of $119.00 million for the quarter, compared to the consensus estimate of $114.25 million. On average, analysts expect Medifast to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Medifast Stock Performance
NYSE:MED traded up $0.13 on Friday, reaching $12.30. The company's stock had a trading volume of 69,508 shares, compared to its average volume of 320,573. The firm has a market cap of $134.52 million, a PE ratio of 68.08 and a beta of 1.05. Medifast has a 1-year low of $11.57 and a 1-year high of $36.30. The business's 50-day moving average price is $13.62 and its two-hundred day moving average price is $16.21.
Analyst Ratings Changes
Separately, DA Davidson dropped their price target on Medifast from $17.00 to $16.50 and set a "neutral" rating on the stock in a research note on Wednesday, February 19th.
Check Out Our Latest Stock Analysis on MED
About Medifast
(
Get Free Report)
Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.
Recommended Stories
Before you consider Medifast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medifast wasn't on the list.
While Medifast currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Like this article? Share it with a colleague.
Link copied to clipboard.
